Trombositopenia Berat pada Ibu Hamil dengan Sistemik Lupus Erythematosus yang Dilakukan Seksio Sesarea
Abstract
Trombositopenia adalah hal yang umum muncul pada kehamilan normal, disebut trombositopenia berat bila jumlah trombosit <50.000 /µL. Komplikasi kehamilan oleh penyakit Lupus Eritematosus Sistemik (Systemic Lupus Erythematosus = SLE) dapat menimbulkan trombositopenia berat patologis. Karena peran penting trombosit dalam pembekuan darah, dilain pihak proses persalinan akan menimbulkan perdarahan, maka dibutuhkan jumlah dan fungsi trombosit yang cukup. Trombositopenia-SLE berderajat berat perlu mendapat terapi untuk meningkatkan jumlah dan fungsi trombosit sebelum menjalani persalinan. Upaya peningkatan jumlah trombosit pada trombositopenia-SLE diawali dengan kortikosteroid sebagai terapi awal, dengan terapi alternatif lanjutan imunosupresif, splenektomi, plasmaferesis, trombopoetic, dan konsentrat trombosit. Pada kasus ini trombositopenia tidak dapat teratasi, sehingga pemeriksaan fungsional pembekuan darah bleeding time dan clotting time digunakan untuk membantu memperkirakan kemungkinan terjadi perdarahan berkelanjutan. Perhatian utama pada pemilihan tehnik anestesi kasus ini adalah kemungkinan terjadi perdarahan berkelanjutan, dalam hal ini dipilih yang dipertimbangkan berisiko terkecil yaitu total intravenous anesthesia (TIVA) dengan ketamin. Perawatan pasca operasi dilaksanakan juga dengan tetap mewaspadai kemungkinan terjadi perdarahan berkelanjutan.
Severe Trombositopenia in Pregnant Woman with Sistemic Lupus Erythematosus Ongoing Caesarean Section
Abstract
Thrombocytopenia is a common occurrence in normal pregnancy, will classified as severe thrombocytopenia if platelet count <50.000/ µL. Pregnancy complicated by Systemic Lupus Erythematosus (SLE) can lead to pathological severe thrombocytopenia. As thrombocytes has a main role in haemostasis, and delivery process will always caused bleeding, thrombocytes needed in proper amount and function. Severe SLE-Thrombocytopenia has to treat aiming higher total thrombocytes and function before delivery. Effort in raising thrombocytes count on SLE-thrombocytopenia patients recommended starting from corticosteroid as first line treatment, followed by any alternatif therapy if thrombocytes count did not responds to corticosteroid therapy, such as immunosuppresif drugs, splenectomy, plasmapharesis, thrombopoetic drugs, and trombocyte concentrate. In this case, severe thrombocytopenia couldn’t be resolved, so then the bleeding time and clotting time taken as tools to estimate blood’s ability to coagulate. The main consideration on choosing anesthesia’s plan in this case is possibility condition to held uncontrolled bleeding. Therefore, the procedure with the lowest risk for maternal and fetal, total intravenous anesthesia with ketamin, had chosen. Caring for post operative SLE-thrombocytopenia patient should never ignoring vigilance for sustainable bleeding.
Downloads
References
Ortega LM, Schultz DR, Lenz O, Pardo V, Contreras GN. Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 2010;19:557–74.
Zen M, Ghirardello A,IaccarinoL,Tonon M, Campana C, Arienti S, Rampudda M, Canova M, Doria A. Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med Wkly 2010;140:187–201.
Petri M. Sex hormones and systemic lupus erythematosus. Lupus 2008; 17:412–15.
Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am 2007; 33:237–52.
PetriM. Hopkins Lupus Pregnancy Center 1987 to 1996. Rheum Dis Clin North Am 1997; 23: 1–13.
Al Arfaj AS, Khalil N. Pregnancy outcome in 396 pregnancies in patients with SLE in Saudi Arabia. Lupus 2010; 19: 1665–73.
Brucato A, Cimaz R, Caporali R, Ramoni V, Buyon J. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol 2011; 40: 27–41.
Izmirly PM, Saxena A, Kim MY, Wang D, Sahl SK, Llanos C, Friedman D, . Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of antiSSA/Ro-associated cardiac neonatal lupus. Circulation 2011; 124(11): 1927–35.
Georgiou PE, Politi EN, Katsimbri P, Sakka V, Drosos AA. Outcome of lupus pregnancy: A controlled study. Rheumatology (Oxford) 2000; 39: 1014–19.
Usha P, Lori R. Maternal thrombocytopenia in pregnancy. Proceedings in Obstetrics and Gynecology, 2013; 3 (1):6.
Ciobanu AM, Colibaba S, Cimpoca B, Peltecua G, Panaitescu AM, Thrombocytopenia in Pregnancy. Maedika 2016; 11 (1): 55–60.
Redjeki IS, Zulfariansyah A., Rachman IA, Prihartono MA, Budipratama D. Prosedur Anestesi Regional dengan Sub Arachnoid Block. Pedoman Praktek Klinis Anestesiologi. 2013; 7–8.
Keputusan Menteri Kesehatan Republik Indonesia Nomor : HK.02.02 / Menkes / 251 / 2015 Bab IV Panduan Anestesi Regional Pedoman Nasional Pelayanan Kedokteran Anestesiologi dan Terapi Intensif, Pengurus Pusat Perhimpunan Dokter Spesialis Anestesiologi dan Terapi Intensif Indonesia, 2015; 33–56.
Mok CC, Lee KW, Ho CT, Lau CS, Wong RW. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology 2000; 39: 399–406.
Leszczyński P, Pawlak-Bus K. New treatment strategy including biological agents in patients with systemic lupus erythematosus. Pol Arch Med Wewn. 2013; 123(9): 482–90.
Jacobs P, Wood L, Dent DM. Splenectomy and the thrombocytopenia of systemic lupus erythematosus. Ann Intern Med. 1986; 105: 971–72.
Gruenberg JC, VanSlyck EJ, Abraham JP. Splenectomy in systemic lupus erythematosus. Am J Surg. 1988; 155: 391–94.
Hall S, McCormick JL Jr, Greipp PR, Michet CJ Jr, McKenna CH. Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. Ann Intern Med. 1985; 102: 325–28.
Boumpas DT, Barez S, Klippel JH, Balow JE. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med. 1990; 112: 674–7.
Maier WP, Gordon DS, Howard RF, Saleh MN, Miller SB, Lieberman JD, et al. Intravenous immunoglobulin therapy in systemic lupus erythematosus – associated thrombocytopenia. Arthritis Rheum. 1990; 33: 1233–39.
Lehembre S, Macario-Barrel A, Musette P, Carvalho P, Joly P. Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus. Ann Dermatol Venereol. 2006; 133: 53–5.
Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ, BIOGEAS STUDY Group. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine. 2008; 87: 345–64.
Traynor AE, Barr WG, Rosa RM, Rodriguez J, Oyama Y, Baker S, et al. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum. 2002; 46: 2917–23.
Lisukova IA, Sizikova SA, Kulagin AD, Kruchkova IV, Gilevich AV, Konenkova LP, et al. High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus. Lupus 2004; 13: 89–94.
The American College of Obstricians and Gynecologists. Thrombosytopenia in pregnancy.Clinical management guidelines for obstetericians-gynecologists. Practice Bulletin 2016; 128(3): e43–53.
Hashimoto H. Glucocorticoid Therapy in Systemic Lupus Erythematosus – Clinical Analysis of 1,125 Patients with SLE. DOI: 10.5772/52044.
Jih DM, Werth VP. Thrombocytopenia after a single test dose of methotrexate. Journal of the American Academy of Dermatology 1998; 39 (2): 349–51.
Mion G, Villevieille T. Ketamine Pharmacology: an update (pharmacodynamics andmolecular aspects, recent findings). CNS Neuroscience & Therapeutics 2013; 19: 370–80.
Tucker AP, Kim YI, Nadeson R, Goodchild CS. Investigation of the potentiation of the analgesic effects of fentanyl by ketamine in humans: a double-blinded, randomised, placebo controlled, crossover study of experimental pain[ISRCTN83088383]. BMC Anesthesiology 2005; 5:2 doi:10.1186/1471-2253-5-2.
Deng XM, Xiao WJ, Luo, MP, Tang GJ, Xu KL. The use of midazolam and small-dose ketamine for sedation and analgesia during local anesthesia. Anesth & Analg. 2001; 93 (5): 1174–7.